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Understanding how oncogenic mutations rewire regulatory protein networks is 
important for rationalizing the mechanisms of oncogenesis and for individualizing anti-
cancer treatments.  We report a chemical phosphoproteomics method to elucidate the 
topology of kinase signaling networks in mammalian cells. We identified >6,000 protein 
phosphorylation sites that can be used to infer > 1,500 kinase-kinase interactions and 
devised algorithms that can reconstruct kinase network topologies from these 
phosphoproteomics data. Application of our methods to primary acute myeloid 
leukemia (AML) and breast cancer tumors quantified the relationship between kinase 
expression and activity, and enabled the identification of hitherto unknown kinase 
network topologies associated with drug resistant phenotypes or specific genetic 
mutations. Using orthogonal methods we validated that PIK3CA wild-type cells adopt 
MAPK-dependent circuitries in breast cancer cells and that the kinase TTK is important 
in AML. Our phosphoproteomic signatures of network circuitry can identify kinase 




Understanding the circuitry and topology of signaling networks driven by protein and lipid 
kinases is important to rationalize the molecular basis of signal transduction and how this 
process is subverted in disease 1. An established approach to infer kinase network topology 
and circuitry entails the use of systematic literature mining methods to compile data on the 
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relationships between enzymes in signaling cascades 2, 3. Overlaying phosphoproteomic data 
onto these literature-mined networks offers a useful starting point for analyzing the impact that 
experimental perturbations have on signal transduction 4. Although informative, particularly 
when used in combination with logic modelling 5, 6, due to pathway popularity and reagent 
availability, literature-mined networks are biased towards well-known kinases and pathways, 
thus restricting the opportunity for new discovery  7. In addition, since they use data from 
different cell types and organisms, such networks consist of composite topologies that are not 
always representative of how signaling may be wired in a given cell population. Aside from in 
silico methods, experimental approaches for kinome analysis entail measuring kinase 
expression 8, 9, their phosphorylation 10, 11, enzymatic activity 12, 13, or a combination of these14, 
15, without revealing new information on the kinase-kinase relationships that define signaling 
cascades and network circuitry. Because of these limitations, comparative systematic analysis 
of biochemical network topologies has so far been restricted to the analysis of metabolic, 
protein-protein interaction and transcription factor networks 16, 17.   
To address the question of how genetic mutations rewire kinase networks 18, and how these 
circuitries in turn regulate cancer phenotypes, here, we first developed a chemical 
phosphoproteomics approach to systematically identify markers of kinase network circuitry. 
By comparing the selectivity profiles of a set of kinase inhibitors with their effects on cellular 
phosphoproteomes, we identified 6,206 kinase-phosphosite (K-P) relationships for 103 
kinases and 1,508 edges (kinase-kinase relationships). Comparative analysis of these 
network circuitry markers modelled differences in topologies across tumors and uncovered 
hitherto uncharacterized connections in these cancer networks. Our study represents a unique 
resource to investigate the relationships between kinase network topology and the phenotypes 




Expectancy of being downstream target (EBDT) algorithm assigns phosphosites to upstream 
kinases 
Most kinase inhibitors inhibit a large number of kinases making it difficult to derive conclusions 
on K-P relationships from phosphoproteomic analysis of cells treated with kinase inhibitors 19, 
20. To overcome this limitation, we developed an algorithm, named expectancy of being 
downstream target (EBDT), which utilizes information on kinase inhibitor selectivity to 
determine the most probable kinase(s) acting upstream of phosphorylation sites present in 
phosphoproteomics data (Fig. 1a, see Supplementary Notes).  
To investigate the validity of the approach, we profiled the target selectivity of 20 kinase 
inhibitors against 403 kinases. These 20 compounds inhibited 135 kinases by >50% (Fig. 1b, 
left panel). To complement these data, we also compiled selectivity data from vendors and the 
literature 21 for 40 compounds that inhibited 312 kinases (Supplementary Dataset 1), 163 of 
which had unique in vitro inhibition patterns across the profiled compounds (Fig. 1c) with no 
bias in terms of kinase families represented (Fig. 1d). Despite employing different assays, 
selectively data from DiscoverX (this study) and literature sources were comparable for 
compounds included in both datasets (Supplementary Fig. 1a). In parallel, we profiled the 
phosphoproteomes of three different cell lines (HL60, MCF7 and NTERA2) treated with the 
same compounds for which we had target specificity data. These experiments were performed 
in biological and technical replicate and required 794 LC-MS/MS runs. In total, we quantified 
23,181 unique phosphorylation sites across all runs using previously reported methods 22, 23 
(Supplementary Dataset 2, Supplementary Fig. 1b, c). We focused the analysis on 
phosphopeptides with a FDR of identification <0.01 and CV (of control) <50%. The number of 
phosphosites that met these stringent criteria were 9,326, 9,416, and 12,591, for HL60, MCF7 
and NTERA2 cell lines, respectively (Supplementary Fig. 1d). To assist the analysis, we 
created a relational database (named ChemPhoPro) with web interface from which these 
phosphosites may be browsed (Supplementary Fig. 2).  
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We next used the EBDT algorithm (Fig. 1a, see Methods section for details) to assign each of 
the quantified phosphorylation sites to kinases acting upstream, leading to the identification of 
2,706, 3,305, and 3,097 phosphosites (for HL60, MCF7 and NTERA2 cell lines) as putative 
downstream targets (PDTs) of 103 kinases (Supplementary Fig. 1e-f). In total, 6,206 unique 
PDTs were assigned to upstream kinases in at least one cell line (Supplementary Dataset 
3).  
PDTs represent a source of K-P relationships that capture well-known K-P associations. 
Furthermore, motif analysis showed the expected associations between kinases and 
phosphorylation motifs (Supplementary Dataset 4), as illustrated in Supplementary Fig. 3a 
for AKT1 and PKCI (which enriched motifs with basic residues at N-term), and CDKs (SP 
motifs with basic residues at C-term), consistent with the substrate specificity of these kinase 
groups 24, 25. Similarly, comparison with computationally predicted kinase-substrate 
relationships using NetworKIN highlighted the predicted kinase in the PDT sets 
(Supplementary Fig. 3b), while comparison with published sources of K-P relationships 
showed that 548 and 375 sites in the PDT dataset were also present in PhosphoSitePlus and 
Signor databases of kinase-substrate relationships, respectively (Fig. 1e). Of note, 5,575 sites 
identified in this study as being PDT were not present in Signor or PhosphoSitePlus (Fig. 1e), 
and we identified PDTs for poorly represented kinases in previous repositories 
(Supplementary Fig. 4a). In total, we mapped 19,410 K-P relationships, which is a 
considerable larger coverage than those provided by PhosphoSitePlus and Signor (10,220 
and 7,237, respectively, Supplementary Fig. 4b). Thus, our study significantly extends our 
knowledge of K-P relationships. 
Since PDTs are readily detectable by mass spectrometry (they were all identified with this 
technique), we reasoned that PDTs would allow inferring kinase activity from phosphoproteins 
experiments with greater depth than when using other repositories as the source of K-P 
relationships. To test this, we measured the phosphoproteomes of a cell line (P31/Fuj) after 
treatment with 6 different kinase inhibitors (Supplementary Fig. 4c). This cell line is unrelated 
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to the panel used to construct the PDT dataset, thus it allowed us to assess the approach in 
an independent model. Out of the 8,100 unique phosphopeptides identified in this experiment, 
1,746 were present in the PDT database, whereas 403 and 228 sites could be mapped to 
PhosphoSitePlus and Signor, respectively (Fig. 1f). These phosphosites were downstream of 
82, 58 and 51 kinases in PDTs, PhosphoSitePlus, and Signor, respectively (Fig. 1f) with the 
average phosphosite per kinase being about 7 times greater when using PDTs as source of 
K-P relationships (Fig. 1f). Thus, overall, when used as the source of Kinase Substrate 
Enrichment Analysis (KSEA, Refs 12, 26), our PDT dataset significantly extends the coverage 
of kinase activity measurements that may be obtained from the interrogation of 
phosphoproteomics data (Supplementary Fig. 4d and Supplementary Dataset 5). 
PDT signatures allow comparative analysis of signaling network topology  
Our study provides the community with a rich set of kinase activity markers that are readily 
measurable by mass spectrometry. However, unlike published repositories of direct kinase-
substrate relationships, phosphosites in PDTs comprise direct and indirect substrates of 
kinases. We reasoned that this feature would allow us to investigate the relationship between 
the 103 kinases for which we identified PDTs. Using the PI3K/AKT/MTOR pathway as an 
example, Fig. 2a illustrates our approach to investigate kinase-kinase relationships and thus 
reconstruct networks from these data; 43 sites were identified to be PDTs of both PI3Kα (gene 
PIK3CA) and mTOR, 38 sites were PDTs of both PI3Kα and AKT1/2 and 25 of both mTOR 
and AKT1/2. This data can be represented in network format (Fig. 2b, edges in these networks 
may be conceptualized as signaling axes). Application of this approach to all other kinases 
with PDTs reconstructed a network consisting of 1,508 edges between 103 kinase nodes with 
weight ≥ 5 sites (Fig. 2c). Each of these edges was defined by 24 phosphorylation sites on 
average (Fig. 2d).  The degree distribution of networks generated using high PDT threshold 
values showed left-skewed (power law) distributions (Fig. 2e), which were different to those 
obtained from randomly generated networks (Fig. 2f). Degree distributions that resemble 
power law distributions are typical of empirical networks, such as the internet and protein 
7 
 
interaction 27, 28. In addition to well-known kinase-kinase associations, these data uncover a 
wealth of hitherto unexplored signaling axes and define a kinase network with unprecedented 
depth. The phosphosites defining network edges are provided as a community resource in 
Supplementary dataset 6 and in the ChemPhoPro website (Supplementary Fig. 2).  
As with the analysis of motifs in PDTs, we found an enrichment of the expected motifs and 
NetworKIN-predicted kinases in the identified edges, consistent with known kinase substrate 
specificities (Supplementary Fig. 5a, Fig. 5c and Supplementary Dataset 4). To confirm the 
biological relevance of the identified K-P relationships in a functional manner, we obtained 
time course phosphoproteomics data from Wilkes et al 6 and quantified PDT group enrichment 
(using the principles of KSEA 12, 26) as a function of treatment with IGF-I or EGF, two agonists 
with well-characterized kinetic effects on cell signaling 29. Fig. 2g illustrates the quantification 
approach with sites in the AKT1/2.PIK3CA PDT group, and Fig. 2h, Supplementary Fig. 5b 
show different signaling axes containing MAPK and PI3K nodes that increased in global 
phosphorylation with kinetics consistent with previous studies 29, 30. In addition, experiment 
using cells treated with kinase inhibitors (Supplementary Fig. 4c) showed a decreased in 
enrichment of axes containing the expected kinases (Supplementary Fig. 5d). Together, 
these data strongly suggest that our groups of phosphorylation sites that define network 
axes/edges are bona fide markers of kinases activities linking the defined network edges. 
Identification of network circuitries in cancer cells of distinct drug resistant phenotypes 
We next investigated the biological relevance and potential of our PDT library to be used for 
comparative analysis of kinase network topology. To this end, we used edge enrichment to 
reconstruct kinase networks in three cell lines (Fig. 3a-c), from which we obtained values of 
centrality for each kinase node (betweenness and degree, Fig. 3d-f). Previous studies have 
shown that, in general, node centrality values are correlated with their importance in 
maintaining network integrity 27, 28. In our analysis, kinase nodes in the PI3K pathway showed 
high centrality values in MCF7 cells relative to NTERA2, whereas MAPK1-3 (ERK) centrality 
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values were higher in the NTERA2 network (Fig. 3g-h and Supplementary Fig. 6a). Of note, 
these data were consistent with the analysis of phosphorylation sites markers of PI3K and 
MAPK pathways (Supplementary Fig. 6b). These observations predicted a key role of 
PI3K/AKT/MTOR in regulating MCF7 biology, whereas the MAPK pathway was expected to 
regulate signaling in NTERA2. Consistent with the prediction, NTERA2 was highly sensitive 
to MEK inhibition, whereas MCF7 was more sensitive to PI3K blockade (Fig. 3i). These data 
suggest that the networks measured using our set of PDTs markers of circuitry encode 
information on signaling activity and cell behavior.   
To investigate the biological relevance of the network circuitries encoded in our PDT dataset 
in a larger and more clinically relevant set of cancer models, we measured our markers of 
network topology in 36 primary acute myeloid leukemia (AML) biopsies. Phosphoproteomics 
and drug sensitivity data for these models have been recently published 15. As reported before 
15, primary AML cells showed highly heterogeneous responses to treatments with inhibitors of 
MEK1/2, FLT3/PKC, PAK isoforms, P38 and CK2 (Fig. 4a). To identify edges in the network 
that may determine drug responses, we constructed partial least square (PLS) models trained 
using 18 randomly selected cases and tested using the remaining 18 cases. The accuracy of 
drug sensitivity prediction ranged from 20% to 45% (Fig. 4b-e and Supplementary Fig. 7), 
thus showing good model fits. Edges connecting kinase nodes known to be targeted by the 
compounds contributed to the models (Fig. 4b-e right panels, Supplementary Fig. 8), thus 
providing confidence on the models’ biological relevance. PLS models using other metrics of 
signaling activity also predicted responses to kinase inhibitors with relatively high accuracy. 
However, the same approaches did not accurately predict overall patient survival 
(Supplementary Fig. 7), suggesting that values of kinase pathway activity and network 
circuitry specifically encode information on responses to drugs that disrupt kinase networks.  
Impact of proteomic and genomic factors on network topology formation 
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We next investigated the proteomic and genomic factors that may determine kinase activity 
and network topology. We first measured the extent of association between kinase expression, 
kinase activity and edge weights in three different primary cancer datasets for which good 
quality phosphoproteomics and protein data are available 15, 31, 32. The analysis of PAK1 across 
69 ovarian cancers (Fig. 5a-c) illustrates the approach that we undertook; while the 
associations between individual PAK1 phosphosite intensities and PAK1 activity (as estimated 
by PAK1 PDT enrichment) were not significant (Fig. 5a), PAK1 estimated activity correlated 
with the sum of its phosphopeptide signals (Fig. 5b, top), but interestingly, not with unmodified 
PAK1 expression (Fig. 5b, middle). The ratio of phosphokinase to total kinase correlated to 
the same extent as un-normalized values (Fig. 5b, bottom, and 5c). Extension of this analysis 
to all identified kinases showed that while the correlation between estimated kinase activity 
(by PDT enrichment) and protein expression was not significant (just 39 out of 88 kinases 
showed positive correlation), phosphokinase expression and estimated kinase activity was 
strongly associated, with 92% (73/79) of these being positively correlated (Fig. 5d, left). 
Similarly, the correlation between phosphokinase expression and edge enrichment was 
positive for 86% (1,194 out of 1,386) of these, and statistically different to the association 
between kinase expression and edge enrichment (p<2.2E-16 by Wilcoxon test, Fig. 5d, right 
panel).  Analysis of AML and breast cancer (BC) datasets also showed greater correlation 
between kinase activity with phosphokinase expression than with protein expression 
(Supplementary Fig. 9a) and was consistent across all three cancer models tested (Fig. 5e). 
The number of kinase substrates used to quantify kinase activity did not determine the 
association between phosphokinase expression and activity (Supplementary Fig. 9b). 
Interestingly, the number of phosphorylation sites on a kinase was proportional to the 
correlation between kinase activity and their phosphorylation extent (Supplementary Fig. 9c) 
but this factor did not contribute to the association between kinase expression and activity 
(Supplementary Fig. 9d). These data suggest that kinases that are phosphorylated at several 
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sites are regulated by overall phosphorylation to a greater extent than kinases that are 
phosphorylated on fewer sites. 
To investigate the elements of kinase network topology associated to common genetic 
mutations, we assessed kinase edge enrichment as a function of genetic mutations in BC and 
AML biopsies. Primary AML cases positive for NRAS G12D mutations enriched kinases 
downstream of the canonical RAS pathway, including MAP2K1, PAK1, PIK3CA and AKT1  
(Supplementary Fig. 10a-c), thus providing further evidence of biological relevance. TTK 
showed high centrality values in the NRAS associated AML network. To confirm the 
involvement of TTK in regulating AML biology, we treated an AML cell panel with CFI-402257, 
a highly specific TTK inhibitor at the concentrations used in this study 33. This compound had 
a greater impact on cell death of six different AML models than inhibitors against kinases of 
current clinical and preclinical interest in this disease (Supplementary Fig. 10d-e), suggesting 
that TTK regulates AML cell death. 
As for primary BC, TP53-mutated and triple negative cases (TNBC) enriched kinases 
associated with cell cycle progression (CDK2, CDK9 and CSNK1E), and with oncogenic 
transformation (ARAF, PDGFRB) (Fig. 6a, Supplementary Dataset 7). Cases positive for 
activating PIK3CA mutations (in helical domain, HD), which are common in this malignancy 34 
35, enriched several PIK3CA/AKT/MTOR axes, thus providing a positive control for the 
analysis. Of note, PIK3CA HD mutations had a greater impact on PI3K and AKT centrality 
values than PIK3CA kinase domain (KD) mutations (Fig. 6b-c), consistent with the distinct 
biochemical and clinical relevance of these mutations 36, 37. To confirm these findings, we took 
advantage of colorectal cancer (CRC) cell lines isogenic for PIK3CA mutations on HD or KD 
domains 35 (Fig. 6d, Supplementary Fig. 11a, and Supplementary Dataset 8). PIK3CA 
mutations activated PI3K/AKT signaling in these cells thus confirming the relevance of the 
models (Fig. 6e, Supplementary Fig. 11b, Supplementary Fig. 13). Phosphoproteomics-
based network analysis showed that, consistent with the data from primary BC, PIK3CA HD 
mutations had greater impact on the network than cells with KD mutations (Fig. 6f). Despite 
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the different genetic backgrounds between primary BC and CRC cell lines, these PIK3CA 
mutant models showed similar enrichment of specific PI3K and MAPK nodes (Fig. 6c). 
Interestingly, cases positive for PIK3CA mutations showed a decrease in the enrichment of 
MAPK-containing edges (Fig. 6c) and the anti-correlation between PI3K and MAPK signaling 
observed across the 86 BC cases was confirmed in PIK3CA mutant isogenic cell lines 
(Supplementary Fig. 11c). These data suggest that the signaling network switches from PI3K 
to MAPK-dependent circuitries in PIK3CA WT cells. To investigate the functional relevance of 
the observed signaling switch, we tested the impact of PI3K and MAPK pathway inhibitors in 
reducing cell viability of the isogenic models. Consistent with the predictions of the models, 
we found that PIK3CA MUT cells were more sensitive to PI3K inhibition whereas trametinib 
(to inhibit the MAPK pathway) preferentially killed PIK3CA WT cells (Fig. 6g and 
Supplementary Fig. 11d).  
Discussion 
Our chemical phosphoproteomics approach to systematically identify K-P relationships takes 
advantage of the well-known promiscuity of most small-molecule kinase inhibitors 38,21. The 
EBDT algorithm is based on the premise that phosphorylation sites inhibited in intact cells with 
the same pattern as the in vitro inhibition fingerprint for a given kinase are expected to be 
downstream of such kinase. Several lines of evidence support the quality of K-P assignments 
using this approach, including the observations that downstream targets of given kinases were 
enriched in phosphorylation motifs associated to such kinases’ consensus substrate 
specificity, and that these behave as expected in cells treated with activators and inhibitors of 
kinase signaling (Fig. 2, Supplementary Figs. 4 and 5 and Supplementary Datasets 5 and 
6).  
Phosphoproteomics measures kinase activities that have occurred in intact cells in a high-
content systematic manner; in this single study we identified >19,564 K-P relationships 
between 6,206 phosphosites,103 kinases and 1,508 network edges, making this the largest 
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(to our knowledge) single dataset of experimentally determined K-P relationship to date. Sites 
in PDT groups are all readily quantifiable by MS and can thus be easily monitored across as 
many experimental conditions as required. This is an important feature because although 
databases of kinase-substrate relationships exist 39, 40, these are biased towards well studied 
kinases 7 and most sites detected in standard phosphoproteomics experiments are not present 
in these databases 12, 14.  
Our approach complements methodologies to identify direct kinase substrates 41-44 because 
the purpose of the EBDT is to obtain phosphosite groups comprising both direct kinase 
substrates and indirect downstream targets, from which kinase activities and network 
circuitries may be inferred. The EBDT algorithm is however restricted to the identification of 
downstream targets of kinases possessing unique inhibition fingerprint patterns. Nevertheless, 
given the vast number of kinase inhibitors available 45, unique inhibition fingerprints may 
already exist for most, if not all, kinases expressed in cells.  
Previous studies have investigated the contribution of transcription and translation to the 
regulation of gene expression 46, but less is known about the global contribution of protein 
expression and phosphorylation to the regulation of overall enzymatic activities. Activation 
loop phosphorylation is a well-known mechanism by which kinase catalysis is regulated 47 and 
the association between single phosphorylation sites and kinase activity has been investigated 
before systematically 13. Here we found several kinases for which the sum of their phosphosite 
intensities correlated with their activity (Fig. 5), suggesting that global phosphorylation may 
be an understudied mechanism of kinase activity regulation.  
Our markers of circuitry highlighted network components associated to recurrent genetic 
mutations in primary BC and AML (Fig. 6 and Supplementary Fig. 10). The anti-correlation 
between PI3K and MAPK edge enrichment in primary BC tumors and in isogenic CRC cell 
lines suggests that therapies that target PI3K signaling may have unintended effects in 
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activating MAPK pathways and this may explain the relatively poor efficacy of single-agent 
PI3K inhibitors for BC treatment 48, 49.  
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Figure 1. Profiling kinase inhibitor fingerprints to assign phosphorylation sites to 
upstream kinases 
(a) Overview of the approach to identify kinase putative downstream targets. The effects of 
inhibitors with well characterized in vitro kinase specificity are matched to their impact on 
cellular phosphoproteomics. The analysis is restricted to kinases expressed in the cell line 
under investigation and to kinases with unique inhibitor fingerprints. (b) Inhibitor fingerprints 
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were determined using the DiscoverX platform for 20 kinase inhibitors, complemented with 
data from the literature. Examples of kinase inhibitor fingerprints for all (left) and a selection 
(right) of kinases using results from the DiscoverX screen. (c) Number of kinases showing 
unique kinase inhibitor fingerprints.  (d) Number of kinases with unique inhibitor fingerprints 
as a function of kinase family. (e) Number of phosphorylation sites in the named databases of 
kinase-phosphosite relationships and their overlap. (f) Sites in the named databases were 
mapped to an independent phosphoproteomics experiment (see Supplementary Fig. 4 for 
details). Bar plots show the number of unique phosphorylation sites mapped to the different 
databases (left), number of kinases for which at least 3 phosphosites were mapped (middle) 





Figure 2. Empirical inference of kinase network circuitry from downstream kinase 
targets 
(a) Illustration of approach to identify markers of network edges for PI3K, MTOR and AKT1/2 
kinase nodes. Each row denotes a single phosphorylation site. Sharing of PDT (in red) allows 
determining markers of kinase-kinase relationships. Data is the compilation of K-P 
relationships found in the cell lines. (b) Edges weights between kinase nodes are defined as 
the number of common PDTs. (c) Network reconstructed from combined PDT data. As is 
common in the representation of biological pathways, edges represent interactions between 
kinases but these are not necessarily direct physical interactions as they may be modulated 
by other molecules. (d) Distribution of edge weights for the 103 kinases that form the network. 
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(e) Degree distribution of identified kinase network as a function of weight cut-off. (f) As in e 
but networks were also constructed from randomly assigned PTDs to network edges. (g) 
Distribution of fold changes of phosphopeptides that belong to the AKT1_2.PIK3CA axis in 
comparison to all phosphopeptides fold changes. (h) Enrichment of kinase axes as a function 





Figure 3. Comparative analysis of network circuitries identifies cell specific kinase 
network topologies 
The figure illustrates approaches to compare kinase signaling circuitry across cellular models. 
A visual approach is shown in (a-c) and mathematical approaches in (d-f). The networks were 
constructed from phosphoproteomics data obtained from the mean of four independent 
experiments. (a, b, c) Kinase nodes showing greater values of centrality are labelled. (d, e, f) 
Betweenness and degree measures of centrality of kinase nodes in the networks shown in a-
c panels. (g, h) Enrichment of kinase axes in MCF7 and NTERA2 cells; z-scores were 
calculated using the PAGE method and p-values using a two-sided Kolmogorov-Smirnov test. 
22 
 
FDR was calculated by adjusting p-values for multiple testing using the Benjamini-Hochberg 
method. These statistics were applied to the mean phosphoproteomics data of four 
independent experiments. For clarity not all edges are labelled. (i) Cell viability as a function 
of treatments with the named inhibitors at the concentrations shown. Data points are mean ± 
SD (n = 3 independent experiments). Trametinib is a MEK1/2 (MAP2K1 and MAP2K2) inhibitor 





Figure 4. Multivariate regression models reveal kinase network topologies associated 
to drug responses 
Responses of primary AML cells to treatment with four different kinase inhibitors was modelled 
using kinase network edge enrichment data, calculated for 36 primary AML cases using their 
published phosphoproteomes 15. (a) Heat-map of drug response data calculated as reduction 
of cell viability as a function of treatment relative to DMSO control. (b, c, d, e) Partial least 
squares (PLS) models were constructed to associate network edges to drug response profiles 
without bias. PLS models, trained using data from 18 randomly selected AML cases, were 
tested in the remaining 18 cases. Left graphs compare predicted with actual responses. Right 




Figure 5. Contribution of kinase expression and phosphorylation to kinase activity and 
network topologies 
(a) Phosphorylation extent of the named PAK1 residues versus PAK1 estimated activity 
across 69 ovarian tumors 50 (each data point represents the quantification of the named 
phosphosites in a tumor and thus, because of missing data points in 50, sample sizes are 
phosphosite specific). Note that not all peptides were identified in all samples. (b) As in (a) but 
correlation was between estimated PAK1 kinase activity and PAK1 protein expression (sum 
of unmodified PAK1 peptides), phosphorylation extent (sum of PAK1 phosphopeptides), or 
their ratio. (c) Statistical significance (by Spearman Rank test) of the associations shown in 
(a) and (b) (n = as in a, b). (d) Systematic analysis of association between kinase activity and 
kinase expression or phosphorylation.  Numbers at the bottom of violin plots refer to positively 
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correlated edges (spearman r > 0, top row) or those with spearman r > 0.31 (p<0.01, bottom 
row). Violin plots show the kernel density of the data, in which probability is related to the width 
of the plot. Boxplots within violin plots (right graph) show the median, interquartile ranges, and 
max-min ranges. Statistical significance of differences between the spearman rank values for 
each analysis was calculated using a two-sided Kruskal-Wallis test. (e) Association between 
extent of kinase phosphorylation and estimated kinase activity across AML, breast and ovarian 





Figure 6. Network analysis of breast cancer identifies impact of genetic mutations on 
kinase network circuitries  
(a) A centrality index was calculated as the product between betweenness and degree values 
for network nodes associated with the mutations shown. The phosphoproteomics data from 
which kinase topologies were determined were obtained from Mertins et al 31. Sample sizes 
are shown in right-hand side table. (b) Difference in kinase network edge enrichment between 
breast cancer biopsies positive for PIK3CA mutations relative to wild-type cases. Fold 
difference was calculated as average in network edge weight in mutant positive tumors (n = 
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10 and 7 for KD and HD, respectively) minus the average in wild-type tumors (n = 54). P-
values were calculated using the Wilcoxon test (two-sided). (c) Enrichment of edges in primary 
BC with HC or KD mutations relative to WT cases and CRC cell lines isogenic for PIK3CA 
mutations. (d) Experimental design for network analysis of CRC cell lines isogenic for PIK3CA 
mutations. (e) Analysis of phosphorylation sites makers of PI3K/AKT and MAPK pathway 
activities in PIK3CA mutant isogenic cell lines. AKT1S1 is also known as PRAS40 and MAPK1 
gene encodes ERK2. Boxplots show median and interquartile ranges. P-values were 
calculated using the Wilcoxon test (two-sided) without adjustments for multiple comparison (n 
= 2 independent experiments performed in technical replicate). (f) Difference in edge 
enrichment in CRC cell lines as a function of the named mutations. Differences and p-values 
were calculated using Wilcoxon test (two-sided) as in (b) (n = 2 independent experiments 
performed in technical replicate). See Supplementary Fig. 11 for further details. (g) The 
named cell lines were treated with 1 µM of the indicated compounds and cell viability 
measured relative to vehicle (DMSO) treated cells. Boxplots show median and interquartile 
ranges. P-values were calculated using a two-sided Wilcoxon test (n = 4 technical replicates). 





Cell culture and inhibitor treatment 
MCF7, NTERA2, DLD1 and HCT116 cells were routinely cultured using DMEM (10% FBS, 
1% penicillin/streptomycin) at 37 oC in a humified atmosphere containing 5% CO2. The culture 
medium for AML suspension cell lines (HL60, P31/Fuj, Kasumi-1, MV4-11, NOMO-1 and THP-
1 cells) was RPMI 1640 (supplemented with 10% FBS, 1% penicillin/streptomycin). Each 
kinase inhibitor was diluted to 10,000 times the desired concentration for treatment using 
DMSO (vehicle). For phosphoproteomics experiments, each compound was then added to 
the cell population at a 1:1000 dilution in the culture medium. Cells were incubated with 1-10 
μM of compound for one hour prior to lysis. The isogenic cell lines DLD1 and HCT116 with 
WT or mutant PIK3CA were provided by Dr Victor E. Velculescu and have been extensively 
characterized in previous publications 35, 51. MCF7 (HTB-22), NTERA2 (CRL-1973), HL60 
(CCL-240), Kasumi-1 (CRL-2724), THP-1 (TIB-202) and MV4-11 (CRL-9591) were purchased 
from ATCC. P31/Fuj was obtained from JCRB Cell Bank (JCRB0091). NOMO-1 was obtained 
from the DSMZ collection (ACC-542). 
Cell lysis  
After cell counting, MCF7, NTERA2, DLD1 and HCT116 cells were seeded in 100 cm2 Petri 
dishes (0.25x106,0.45x106, 0.05x106  and 0.2x106cells/mL, respectively) and maintained in an 
incubator overnight at 37 oC and 5% CO2. Cells were washed twice with cold PBS 
supplemented with 1 mM Na3VO4 and 1 mM NaF and lysed in 500 uL urea buffer (8 M urea 
in 20 mM in HEPES pH 8.0 supplemented with 1 mM Na3VO4, 1 mM NaF, 1 mM Na4P2O7 and 
1 mM sodium β-glycerophosphate). For HL60 and P31/Fuj, 10 mL of cell suspension were 
seeded in T25 flasks (0.6x106 and 1x106 cells/mL, respectively) and maintained in an 
incubator overnight at 37 oC and 5% CO2. Cell were harvested by centrifugation at 500 xg at 
4 oC for 5 min, washed twice with cold PBS supplemented with 1 mM Na3VO4 and 1 mM NaF, 
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snap frozen and stored at -80  oC until further processing. Cell pellets were lysed in urea buffer 
and cell lysates were homogenized by sonication for 10 cycles of 30s on 35s off (Diagenode 
Bioruptor® Plus, Liege, Belgium). Insoluble material was removed by centrifugation at 16,000 
xg for 15 min at 4 oC and protein in the cell extracts was quantified by bicinchoninic acid (BCA) 
analysis (Thermo Fisher Scientific; cat 23225). 
Sample preparation for proteomics and phosphoproteomics analysis 
For phosphoproteomic analyses, we used published methods 52-54 with some modifications. 
Drug treatment experiments were performed twice (biological duplicate) and each experiment 
was analyzed in technical duplicate). Briefly, 350 µg of protein were reduced and alkylated by 
sequential incubation with 10 mM DTT and 17 mM iodoacetamyde for 1h. The urea 
concentration was diluted to 2 M with 20 mM HEPES (pH 8.0) and 100 µL of conditioned 
trypsin beads (50% slurry of TLCK-trypsin) (Thermo Fisher Scientific; cat. 20230) conditioned 
with 3 washes of 20 mM HEPES (pH 8.0) were added and the samples incubated for 16 hours 
at 37 oC with agitation. Trypsin beads were removed by centrifugation at 2,000 xg for 5 min at 
4 oC.  
Following trypsin digestion, peptide solutions were desalted using 10 mg OASIS-HLB 1cc 
cartridges (Waters; cat. WAT094225). Briefly, OASIS cartridges were accommodated in a 
vacuum manifold (-5 mmHg), activated with 1 mL acetonitrile (ACN) and equilibrated with 1.5 
mL washing solution (1% ACN, 0.1% TFA). After loading the samples, cartridges were washed 
twice with 0.75 mL of washing solution. Peptides were eluted with 250 µL of glycolic acid buffer 
1 (1 M glycolic acid, 50% ACN, 5% TFA) for phosphoproteomic analysis or with 250 µL of 
ACN solution (30% ACN, 0.1% TFA) for proteomics analysis. Eluted peptides were, dried in a 
speedvac (RVC 2-25, Martin Christ Gefriertrocknungsanlagen GmbH, Osterode am Harz, 
Germany) and stored at -80 oC. 
Phosphopeptides were enriched from total peptide digests using titansphere TiO2 beads (GL 
Sciences; cat. 5020-75010) as previously described with some modifications 23. Sample 
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volumes were normalized to 0.5 mL using glycolic acid buffer 2 (1 M glycolic acid, 80% ACN, 
5% TFA), and 25 µL of TiO2 beads (50% slurry in 1% TFA) were added to the peptide mixture, 
which was then incubated for 5 min at room temperature with agitation and centrifuged for 30s 
at 1,500 xg. For each sample, 80% of the supernatant was transferred to fresh tubes and 
stored in ice; the remaining 20% was used to re-suspend the bead pellets and these were 
loaded into an empty prewashed PE-filtered spin tips (Glygen; cat TF2EMT) and packed by 
centrifugation at 1,500 xg for 3 min. After loading the remaining volume of the supernatant by 
centrifugation at 1,500 xg for 3 min onto the packed spin tips, these were sequentially washed 
with 100 µL of glycolic acid buffer 2, ammonium acetate buffer (100 mM ammonium acetate 
in 25% ACN) and 10% ACN by centrifugation for 3 min at 1,500 xg. For phosphopeptide 
recovery, the addition of 50 µL of 5% ammonium water followed by centrifugation for 3 min at 
1,500 xg was repeated 4 times. Eluents were snap frozen in dry ice, dried in a speed vac and 
peptide pellets stored at -80 oC.  
Mass Spectrometry 
For phosphoproteomics, peptide pellets were re-suspended in 18 µL of reconstitution buffer 
(3% ACN, 0.1% TFA, containing 20 fmol/µL digested yeast enolase) and 5 µL were loaded 
onto an LC-MS/MS system consisting of a Dionex UltiMate 3000 RSLC directly coupled to an 
Orbitrap Q-Exactive Plus mass spectrometer (Thermo Fisher Scientific). For proteomics, 
pellets were re-suspended in reconstitution buffer at a final concentration of 0.5 µg/µL and 2 
µL were injected in the LC-MS/MS system, using mobile phases A (3% ACN; 0.1% FA) and B 
(100% ACN; 0.1% FA). Peptides were trapped in a μ-precolumn (Acclaim PepMap μ-
Precolumns; cat. 160454) and separated in an analytical column (Acclaim PepMap 100 C18; 
cat. 164261). The following parameters were used: 3% to 23% B gradient for 60 min 
(phosphoproteomics) or 120 min (proteomics) at a flow rate of 0.3 µL/min. Samples were 
shuffled in the LC-MS/MS autosampler before loading. 
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As they eluted from the nano-LC system, peptides were infused into the online connected Q-
Exactive Plus system operating with a 2.1s duty cycle. Acquisition of full scan survey spectra 
(m/z 375-1,500) with a 70,000 FWHM resolution was followed by, data-dependent acquisition 
in which the 15 most intense ions were selected for HCD (higher energy collisional 
dissociation) and MS/MS scanning (200-2,000 m/z) with a resolution of 17,500 FWHM. A 30 
s dynamic exclusion period was enabled with an exclusion list with 10 ppm mass window. 
Overall duty cycle generated chromatographic peaks of approximately 30 s at the base, which 
allowed the construction of extracted ion chromatograms (XICs) with at least 10 data points. 
The mass spectrometry phosphoproteomics data have been deposited to the 
ProteomeXchange Consortium via the PRIDE 55 partner repository with the dataset identifier 
PXD015943. 
Peptide identification from tandem mass spectrometry data 
Mascot Daemon 2.5.0 was used to automate peptide identification from MS data. Peak list 
files (MGFs) from RAW data were generated with Mascot Distiller v2.5.1.0 and loaded into the 
Mascot search engine (v2.5) 56. The searches were performed against the SwissProt 
Database (SwissProt_Sep2014_2015_12.fasta) with a FDR of ~1% and the following 
parameters: 2 trypsin missed cleavages, mass tolerance of ±10 ppm for the MS1 scans and 
±25 mmu for the MS/MS scans, carbamidomethyl of Cys as a fixed modification, PyroGlu on 
N-terminal Gln and oxidation of Met as variable modifications. For phosphoproteomics 
experiments Phosphorylation on Ser, Thr, and Tyr was also included as variable modifications.  
Peptide quantification from MS1 data 
Label-free quantification was performed as described before 12, 23, 54. Pescal software 57 was 
used to automate the generation of extracted ion chromatograms (XICs) for all the peptides 
identified in at least one sample across all samples, after applying retention time alignment 
based on common peptide identifications in pair-wise run to run comparisons. Pescal 
functionality is similar to that provided by other packages 58-60. XICs were constructed with ± 7 
32 
 
ppm and ± 1.5 min mass and retention time windows, respectively. Peak area values of 2 
technical replicates and two biological replicates per condition were averaged after 
normalization to total sample peak area intensity.  
Kinase Enrichment using ATP/ADP Desthiobiotin 
Kinase enrichment with desthiobiotin-ATP and –ADP probes was performed using the ActivX 
kinase enrichment kits (Thermo Fisher Scientific; cat. 88310) according to the manufacturer’s 
instructions. Eluents were dried in a speed vac and stored at -80 oC. Peptide pellets were 
resuspended in 20 µL of reconstitution buffer (20 fmol/µL digested yeast enolase in 3% ACN, 
0.1% TFA) and 5 µL were loaded onto the LC-MS/MS system. 
Western blotting 
Cells were washed twice with ice-cold PBS (supplemented with 1 mM Na3VO4 and 1 mM NaF). 
Cells were scraped and the resulting lysate collected in 150 μL of RIPA buffer (50 mM Tris-
HCl, pH 7.6, 150 mM NaCl, 1 mM EDTA, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS) 
supplemented with 1 mM Na3VO4, 1 mM NaF, 1X protease inhibitor cocktail, 1 mM PMSF and 
0.5 μM okadaic acid. Cell lysates were sonicated for 10 minutes and centrifuged at 16,000 xg 
for 15 min at 4 oC. 55-60 μg of protein extract were analyzed in 4-12% precast commercial 
gels (NuPAGE Novex 4-12% Bis-Tris Midi Gel 1.0 mm). The buffer used for protein 
electrophoresis was NuPAGE MOPS SDS running buffer 20x. 10 mM DTT and NuPAGE LDS 
sample buffer 4x were used to prepare the samples. Electrophoresis was run at room 
temperature using a constant voltage. After electrophoresis, gels were washed in transfer 
buffer (10% methanol, 0.1% NuPAGE Antioxidant diluted in NuPAGE transfer buffer 20x) for 
10 min. Then, the proteins separated were transferred to a nitrocellulose membrane (iBlot Gel 
Transfer Stacks Nitrocellulose) for 13 minutes, applying a constant voltage. After blocking for 
non-specific binding, the membranes were incubated for 14 h at 4 oC with primary antibody. 
Antibodies against GAPDH or β-Actin were used to quantify and normalize protein expression. 
Following this, after several washes membranes were incubated with secondary antibody 
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against mouse or rabbit immunoglobulin conjugated with peroxidase. Finally, membranes 
were incubated for 1 min with 1X SuperSignal West Pico ECL solution, which afforded a 
chemiluminiscence reaction. Antibody affinity was then visualized using a ChemiDoc system 
and the bands were quantified using Image Studio Lite (v5.2). 
Cell Viability assay 
AML suspension cell lines (HL60, P31/Fuj, Kasumi-1, MV4-11, NOMO-1 and THP-1 cells) 
were seeded in 96-well plates and treated with vehicle or 10 to 1000 nM of the indicated 
inhibitor for 72 hours. Trypsin was used for cell dissociation from adherent cell lines (MCF7, 
NTERA2, DLD1 and HCT116). Cells were stained with Guava ViaCount reagent (Merck 
Millipore; cat. 4000-0040) according to the manufacturer’s instructions. Viability was measured 
with a Guava PCA cell analyzer (Guava Technologies Inc, CA, USA) to generate flow 
cytometry data, which were analyzed using CytoSoft (v2.5.7). Compound testing was 
performed in four technical replicates and three biological replicates. Viability and cell death 
values were averaged and expressed relative to vehicle control. 
Kinase inhibitor selectivity datasets 
The selectivity of a set of 20 kinase inhibitors was profiled using the DiscoverX platform 61. 
Compounds were screened at 200 nM. Selectivity data for other compounds were obtained 
from the literature 21, 62. Inhibitor selectivity data was normalized on a scale of 0 to 1 (where 0 
is inhibition and 1 is no inhibition) with the expression (xi – min(x)) / (max(x) –min(x)), where 
xi is the inhibitor data point for a given kinase and x is the vector of inhibition values for all 
kinases for a given compound. An inhibition value of 0 was given to kinase inhibition data 
points in cases when compounds are reported to inhibit such kinase but no actual degree of 




Peptides were parsed from Mascot DAT files using Python scripts and compared to data 
obtained from searches against decoy databases. Probability of false discovery (False 
discover rate, FDR) was determined for each peptide by comparing data to decoy searches 
at several thresholds of Mascot expectancy and mass accuracy windows. FDR values for each 
phosphopeptides are shown in Supplementary Dataset 2. The signals of phosphopeptides 
containing the same phosphorylation site were added and quantile normalized.  
To apply the EBDT algorithm we selected > 50% in vitro inhibition as threshold for determining 
kinase inhibitor fingerprints, and two-fold decrease of phosphosite intensity as a function of 
kinase inhibitor treatment (with unadjusted p<0.02) as heuristic thresholds of significance as 
these thresholds led to false discovery <0.05 (as estimated with the analysis of randomly 
permuted data).  After parameter tuning (Supplementary Fig. 12), final PDTs were 
assembled by selecting sites with kinase-site ratios >0.75 for kinases with rank >0.8.  Highly 
homologous kinases, such as AKT1 and AKT2, and MAPK1 and MAPK3 (also known as ERK2 
and ERK1, respectively) were grouped into single entities. 
In addition to being submitted to PRIDE, the data is reported in a website that integrates prior 
knowledge from a range of sources including UniProt, and experimental data newly generated 
in this study from DiscoverX assays and phosphoproteomic experiments. To manage these 
disparate data, we created a relational database in SQLite (3.24.0) containing tables 
describing proteins (including kinases), perturbagens, substrates (including PDTs) and the 
relationships between these entities. The database was populated using bespoke software 
implemented in Python (3.7.0) that imports data, resolves issues of inconsistent nomenclature, 
and formats the data for insertion into the database. This software was subsequently extended 
to insert results of our analysis, notably the identified PDTs, into the database. A front end for 
the database was created using Python, Flask (1.0.2) and other libraries to allow the 
community to browse the database (see Supplementary Fig. 2). 
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Networks were constructed and analyzed using the iGraph R package (v. 1.2.2). Partial least 
squares (PLS) was performed using the caret R package 63 (v6.0-80) with resampling model 
building using randomly chosen 18 samples (LOOCV train control method) and RMSE metric. 
Model performance was tested using the remaining 18 samples.  
Statistics 
Statistical analyses were performed in R and Python. Unpaired, two-tail Student’s t-test was 
used to assess significance in phosphoproteomics data. Where applicable, p-values were 
adjusted for multiple testing using Benjamini-Hochberg method.  
Kinase and network edge enrichment was assessed by comparing the distributions of fold-
changes (in Log2 scale) of phosphopeptides belonging to PDTs or network edge groups 
against the distribution of all phosphopeptide fold-changes 9, 12. This was achieved by 
calculating z-scores (using the PAGE method 12, 23, 64, to evaluate magnitude of enrichment) 
and p-values (using the Kolmogorov-Smirnov test 65 to assess statistical significance), which 
were adjusted using the Benjamini-Hochberg method.  
Motif enrichment in network edge groups was calculated as Log2[(a/b)/(x/y)] where: a, number 
of phosphorylation sites in edge group with a given motif; b, number of phosphorylation sites 
in edge group; x, total number of phosphorylation sites with motif; y, total number of 
phosphorylation sites. Enrichment of empirically determined phosphorylation sites in predicted 
substrates for kinases was done by matching to NetworKIN dataset version 3.1 66. Enrichment 
was calculated as (a/b)/(x/y), where a, number of PDTs for a given kinase in 
NetworKIN/Netphorest group; b, total number of PDTs for same kinase; x, number of 
NetworKIN/Netphorest substrates for kinase group; y, total number of NetworKIN/Netphorest 
substrates. 
Life Sciences Reporting Summary 
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Further information on research design is available in the Nature Research Reporting 
Summary linked to this article 
Data Availability 
The mass spectrometry phosphoproteomics data have been deposited to the 
ProteomeXchange Consortium via the PRIDE partner repository 55 with the dataset identifier 
PXD015943. Submission details: 
Project Name: Chemical phosphoproteomics reveals kinase network topologies associated 
to genotypes and phenotypes of cancer cells. 
Project accession: PXD015943 
Project DOI: Not applicable 
Figures with associated raw data: Figure 1, 2 and 6. 
Additional availability from ChemPhoPro.org 
Code Availability 
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